ClinicalTrials.gg
CompletedNCT01566396Updated Oct 19, 2012

Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles

An interventional study of A3F in Facial Wrinkles, sponsored by Pollogen. Completed at 2 sites in United States. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-19.

Sponsored by Pollogen (part of Lumenis Be Ltd.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Study summary

The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. This study was designed in order to evaluate the safety and efficacy of the A3F for treatment of facial wrinkles.

Read the detailed description

The need for cosmetic facial enhancement procedures with minimal down time and low risk has led to the development of methods for non-surgical skin rejuvenation. Various ablative lasers were developed, which remove the full skin surface in a controlled manner1,2. However, the prolonged recovery and the significant risks prompted the development of fractional lasers which ablate the skin in a fractional manner, leaving untreated areas to improve healing process3. In the past few years, fractional RF systems have been introduced that enable controlled skin resurfacing accompanied with dermal collagen remodeling4,5,6. The new 3F Applicator (A3F, trade name TriFractional) from Pollogen™ is designed to enable skin resurfacing and treatment of wrinkles using radiofrequency energy.

The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. This study was designed in order to evaluate the safety and efficacy of the A3F for treatment of facial wrinkles.

02

Conditions studied

  • Facial Wrinkles

Keywords

  • Fractional,
  • RF,
  • Wrinkles
  • Safety
  • Efficacy
  • treatment
03

In context

Lead sponsor

Pollogen is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted before Pollogen became part of Lumenis Be Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject read, understood and signed the Consent Form
  2. Healthy female/male aged 35 65 years,
  3. Fitzpatrick wrinkle classification score 3 and above
  4. Fitzpatrick skin type 2-5
  5. Subject is capable of reading, understanding and following instructions of the procedure to be applied.
  6. Subject is able and willing to comply with the treatment and follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
  2. Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
  3. Subject has current or history of cancer, especially skin cancer or premalignant moles or is undergoing any form of treatment for active cancer.
  4. Subject has severe concurrent conditions such as epilepsy, lupus or cardiac disorders.
  5. Subject has poorly controlled endocrine disorders such as diabetes.
  6. Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
  7. Subject has an impaired immune system due to diseases such as or AIDS, or use of immunosuppressive medications.
  8. Subject has a condition that could be negatively affected by heat, including any history of diseases stimulated by heat, such as recurrent Herpes Simplex (in the treatment area).
  9. Subject has diminished or exaggerated perception of temperature changes.
  10. Subject has significant concurrent skin conditions affecting areas to be treated such as sores, hemorrhages or risk of hemorrhages, septic conditions, psoriasis, eczema and rash as well as very dry and fragile skin.
  11. Subject has history of collagen disorders, keloid formation and abnormal wound healing.
  12. Subject has had previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans on such treatment during the course of the study, or before complete healing has occurred.
  13. Subject has had Botox injections in the treatment area within 6 months prior to initial treatment
  14. Subject has had natural fillers within 9 months prior to initial treatment
  15. Subject has synthetic fillers, injected chemical substance or gold/plastic threads in the treatment area.
  16. Subject takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing such as prolonged regime, tetracyclines, or St. John's Wort for the last 3 months.
  17. Subject has used oral isotretinoin (Accutane or Roaccutan) within 6 months prior to study enrollment or plans use during the course of the study.
  18. Subject has history of bleeding coagulopathies or use of anticoagulants.
  19. Use of non-steroidal anti inflammatory drugs (NSAIDS, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment
  20. Tattoo or permanent makeup in the treated area
  21. Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
  22. Concurrent participation in any other study.
  23. Subject has mental disorders that in the opinion of the Investigator would be interfere with ability to comply with the study requirements.
  24. Subject is allergic to the topical anesthetic used in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    A3F

    A3F, Fractional RF treatment

    Device: A3F

Interventions

  • DeviceA3F

    A3F fractional RF treatments for facial wrinkles

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of the 3F Applicator (A3F) for treatment of facial wrinkles.

    The safety of using the 3F Applicator (A3F) for treatment of facial wrinkles a will be established by physician's assessment/observation of adverse events. AEs will be tabulated by severity and relation to treatment.

    Time frame: 6 months

Secondary outcomes

  1. To evaluate the efficacy of the 3F Applicator (A3F) for treatment of facial wrinkles.

    Efficacy of using the 3F Applicator (A3F) for treatment of facial wrinkles will be established by level of wrinkle reduction. The treated area will be photographed, using high-resolution macro photography prior to the treatments and at the follow up visits. The pre - and post-treatment photographs will be compared and scored by two independent uninvolved physicians.

    Time frame: 6 months

07

Study locations

2 sites
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Research Across America
    Plano, Texas 75093, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Mar 29, 2012
Start
Mar 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Oct 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01566396
Lead sponsor
Pollogen
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Mar 2012
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Oct 19, 2012

Study contacts

Mira Barki, PhD
study director · Pollogen Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion